Coffee, tea and caffeine intake and the risk of non-melanoma skin cancer: a review of the literature and meta-analysis.

Saverio Caini, Maria Sofia Cattaruzza, Benedetta Bendinelli, Giulio Tosti, Giovanna Masala, Patrizia Gnagnarella, Melania Assedi, Ignazio Stanganelli, Domenico Palli, Sara Gandini

Journal: European journal of nutrition 2017;56(1):1-12

PMID: 27388462

Abstract

PURPOSE

Laboratory studies suggested that caffeine and other nutrients contained in coffee and tea may protect against non-melanoma skin cancer (NMSC). However, epidemiological studies conducted so far have produced conflicting results.

METHODS

We performed a literature review and meta-analysis of observational studies published until February 2016 that investigated the association between coffee and tea intake and NMSC risk. We calculated summary relative risk (SRR) and corresponding 95 % confidence intervals (95 % CI) by using random effects with maximum likelihood estimation.

RESULTS

Overall, 37,627 NMSC cases from 13 papers were available for analysis. Intake of caffeinated coffee was inversely associated with NMSC risk (SRR for those in the highest vs. lowest category of intake: 0.82, 95 % CI 0.75-0.89, I  = 48 %), as well as intake of caffeine (SRR 0.86, 95 % CI 0.80-0.91, I  = 48 %). In subgroup analysis, these associations were limited to the basal cell cancer (BCC) histotype. There was no association between intake of decaffeinated coffee (SRR 1.01, 95 % CI 0.85-1.21, I  = 0) and tea (0.88, 95 % CI 0.72-1.07, I  = 0 %) and NMSC risk. There was no evidence of publication bias affecting the results. The available evidence was not sufficient to draw conclusions on the association between green tea intake and NMSC risk.

CONCLUSIONS

Coffee intake appears to exert a moderate protective effect against BCC development, probably through the biological effect of caffeine. However, the observational nature of studies included, subject to bias and confounding, suggests taking with caution these results that should be verified in randomized clinical trials.

Address: Cancer Risk Factors and Lifestyle Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Via delle Oblate 2, 50139, Florence, Italy. [email protected].; Department of Public Health and Infectious Diseases, Faculty of Medicine, Policlinico Umberto I, "Sapienza" University, Rome, Italy.; Cancer Risk Factors and Lifestyle Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Via delle Oblate 2, 50139, Florence, Italy.; Division of Dermatoncological Surgery, European Institute of Oncology, Milan, Italy.; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.; Skin Cancer Unit, Scientific Institute of Romagna for the Study and Treatment of Cancer, IRCSS, IRST, Meldola, Italy.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.